(Q57823598)

English

The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC–IV epithelial ovarian cancer

article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16890277%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16890277%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

0 references

1 reference

based on heuristic

inferred from title

William R Jarnagin

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16890277%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

11

object named as

Dennis S Chi

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16890277%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Richard R Barakat

10

object named as

Richard R Barakat

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16890277%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

3

object named as

Yukio Sonoda

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16890277%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Nadeem R. Abu-Rustum

2

object named as

Nadeem R Abu-Rustum

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16890277%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Ronald P DeMatteo

8

object named as

Ronald P DeMatteo

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16890277%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Douglas A Levine

4

object named as

Douglas A Levine

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16890277%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Elizabeth A Poynor

5

object named as

Elizabeth A Poynor

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16890277%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Eric L Eisenhauer

1

object named as

Eric L Eisenhauer

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16890277%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Carol Aghajanian

6

object named as

Carol Aghajanian

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16890277%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

author name string

Michael I D'Angelica

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16890277%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

language of work or name

0 references

publication date

4 August 2006

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16890277%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16890277%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

103

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16890277%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16890277%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1083-1090

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16890277%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

Prognostic factors in advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

A prognostic model for ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

Identification of prognostic factors in advanced epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

The impact of subspecialty training on the management of advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

A critique of surgical cytoreduction in advanced ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

Does debulking surgery improve survival in biologically aggressive ovarian carcinoma?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

Complete cytoreduction: is epithelial ovarian cancer confined to the pelvis biologically different from bulky abdominal disease?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

Resection of diaphragmatic peritoneum and muscle: role in cytoreductive surgery for ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

Diaphragm resection for ovarian cancer: technique and short-term complications

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

Splenectomy during primary maximal cytoreductive surgery for epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

Splenectomy in recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

Splenectomy in the context of primary cytoreductive operations for advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

Aggressive surgical effort and improved survival in advanced-stage ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

Primary peritoneal serous papillary carcinoma: a new epidemiologic trend? A matched-case comparison with ovarian serous papillary cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma—a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

The cavitational ultrasonic surgical aspirator for cytoreduction in advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

The effect of bowel resection on survival in advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

Systematic Aortic and Pelvic Lymphadenectomy Versus Resection of Bulky Nodes Only in Optimally Debulked Advanced Ovarian Cancer: A Randomized Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.06.028

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.YGYNO.2006.06.028

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16890277%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16890277%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57823598&oldid=1955663953"